LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Listă Acțiuni・Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

Închisă

SectorSănătate

492.82 1.27

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

491.57

Maxim

495.72

Indicatori cheie
By Trading Economics
Venit	-314M 1.7B
Vânzări	-1.2B 11B
P/E Medie Sector	24.631 50.102
EPS	5.44
Randament dividend	0.39
Marjă de profit	15.048
Angajați	125,000
EBITDA	-905M 2.3B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+25.87% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	0.39% 2.33%
Următoarele câștiguri	22 iul. 2026
Data viitoare de dividende	15 iul. 2026
Următoarea dată ex-dividende	15 iun. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-29B 167B
Deschiderea anterioară	491.55
Închiderea anterioară	492.82

Sentimentul știrilor

By Acuity

35%

65%

96 / 344 Clasament în Healthcare

Thermo Fisher Scientific Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 apr. 2026, 13:56 UTC

Câștiguri

Thermo Fisher Profit Up, Warns of Inflation from Iran War -- Update

23 apr. 2026, 10:28 UTC

Câștiguri

Thermo Fisher Posts Higher 1Q Profit, Revenue

29 ian. 2026, 11:34 UTC

Câștiguri

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

29 oct. 2025, 10:51 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

23 oct. 2025, 20:49 UTC

Câștiguri

Correction to Thermo Fisher Article on Oct. 22

22 oct. 2025, 10:28 UTC

Câștiguri

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

15 mai 2026, 10:45 UTC

Market Talk

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

23 apr. 2026, 10:01 UTC

Câștiguri

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

23 apr. 2026, 10:01 UTC

Câștiguri

Thermo Fisher: Well Positioned to Deliver Strong Year >TMO

23 apr. 2026, 10:00 UTC

Câștiguri

Thermo Fisher 1Q Net $1.65B >TMO

23 apr. 2026, 10:00 UTC

Câștiguri

Thermo Fisher 1Q Adj EPS $5.44 >TMO

23 apr. 2026, 10:00 UTC

Câștiguri

Thermo Fisher 1Q EPS $4.43 >TMO

23 apr. 2026, 10:00 UTC

Câștiguri

Thermo Fisher 1Q Rev $11.01B >TMO

24 mar. 2026, 12:04 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

24 mar. 2026, 12:00 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

29 ian. 2026, 11:01 UTC

Câștiguri

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

29 ian. 2026, 11:00 UTC

Câștiguri

Thermo Fisher: Entering 2026 From Position of Strength >TMO

29 ian. 2026, 11:00 UTC

Câștiguri

Thermo Fisher 4Q Net $1.96B >TMO

29 ian. 2026, 11:00 UTC

Câștiguri

Thermo Fisher 4Q Rev $12.22B >TMO

29 ian. 2026, 11:00 UTC

Câștiguri

Thermo Fisher 4Q EPS $5.21 >TMO

29 ian. 2026, 11:00 UTC

Câștiguri

Thermo Fisher 4Q Adj EPS $6.57 >TMO

29 oct. 2025, 10:06 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

29 oct. 2025, 10:05 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

29 oct. 2025, 10:05 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

29 oct. 2025, 10:04 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

29 oct. 2025, 10:00 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

22 oct. 2025, 10:01 UTC

Câștiguri

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

22 oct. 2025, 10:00 UTC

Câștiguri

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

22 oct. 2025, 10:00 UTC

Câștiguri

Thermo Fisher 3Q Adj EPS $5.79 >TMO

22 oct. 2025, 10:00 UTC

Câștiguri

Thermo Fisher 3Q Rev $11.12B >TMO

Comparație

Modificare preț

Thermo Fisher Scientific Inc Așteptări

Obiectiv de preț

By TipRanks

25.87% sus

Prognoză pe 12 luni

Medie 613.27 USD 25.87%

Maxim 685 USD

Minim 490 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruThermo Fisher Scientific Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

18 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 18 analiști care au acordat evaluări ale acțiunilor Thermo Fisher Scientific Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

96 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar